Summary.-BALB/c mice born to and nursed by females immunized against MSV-M showed a reduced tumour incidence and a high tumour regression rate following MSV-M injection at 7-14 days of age. Females immunized long before mating could also confer protection to their offspring whereas females immunized after parturition could not. A reduced number of tumours was observed in 3 out of 14 MSV-M injected litters whose mothers had been previously exposed to the virus while nursing infected offspring. Sera from suckling mice born to and nursed by immunized mothers contained MSV-M neutralizing antibody as shown by an in vitro focus reduction assay. Cell-free extracts from mice which developed leukaemia after MSV-M inoculation were tested for oncogenic activity in 1-week old mice. Out of 6 extracts, 4 induced typical MSV-M tumours and 2 caused leukaemias.
BIOLOGICAL and immunological studies of Moloney murine sarcoma virus (MSV-M)-induced tumours in mice indicate that neoplastic cells release infectious virus and possess specific surface antigens capable of inducing an immune reaction in the competent host (Fefer, McCoy and Glynn, 1967a) . A high incidence of spontaneous tumour regression does in fact occur in adult mice injected with MSV-M (Fefer, McCoy and Glynn, 1967b) . In MSV-M injected neonates or immunosuppressed adults, most of the ensuing tumours grow progressively and ultimately cause the death of the host (Fefer et al., 1967b; Shachat, Fefer and Moloney, 1968; Law, Ting and Allison, 1968; Hook, Chirigos and Chan, 1969) . Both cell mediated and humoral immunity seem to be responsible for tumour regression although their respective roles are,still not clearly understood.
MSV-M is readily neutralized in vitro by incubation with sera from MSV-M immunized mice . In addition, MSV-M induced primary and transplanted tumours are inhibited by injections of immune sera (Bubenik, Turano and Fadda, 1969; Pearson, Redmon and Bass, 1973) . In the present study, the possibility of preventing MSV-M Immunization procedure.-Three-to 4-month old normal females were immunized soon after mating by intraperitoneal (i.p.) injection with 0-20 ml of 0-01 gEq tumour extract. A second i.m. injection of 0-20 ml of 0 1 gEq was given 7-10 days later and a third and final injection of 0-20 ml of 0.01 gEq was given i.p. 7-10 days after parturition (which was the same time at which the offspring were inoculated). Another group of female mice were immunized post partum and received the same doses of tumour extract as above on Days 1, 6 and 12 following parturition. A third group consisted of females which had previously nursed an MSV-M inoculated litter and were therefore considered virus " exposed ". A last group of females received 3 immunizing injections 6-29 weeks before mating. This group included some mothers from the first group who were subsequently re-mated. None of the variously treated mothers developed MSV-M tumours as a result of the immunization.
Neutralization test.-The in vitro test for virus neutralizing antibodies was performed by a focus reduction method (Hartley and Rowe, 1966) . Briefly, blood was collected from the retro-orbital sinus of immunized mothers and their litters 10-16 days after parturition, at a time corresponding approximately to MSV-M inoculation in suckling mice. The sera were pooled, inactivated at 56°C for 30 min, and incubated at an appropriate dilution for 60 min at room temperature with 40 FFU (focus forming units) of MSV-M. Sera from 2 normal mothers and their respective litters were used as controls. The mixture of serum and MSV-M was then assayed for focus formation on DEAE-dextran treated NIH/3T3 mouse cells, plated at concentrations of 105 in 60 mm plastic petri dishes (Greiner and Sohme, Niirtingen, Germany).
The cultures were made in duplicate using Eagle's minimum essential medium supplemented with 10% foetal calf serum (Grand Island Biological Company, Grand Island, New York), and antibiotics. Foci were counted on the 7th day.
RESULTS

Prevention of MSV-M tumour induction in offspring of immunized mothers
The protective effects of immunized mothers on tumour induction in their offspring were studied by challenging 1-2 week old mice with graded doses of MSV-M tumour extracts. These results are summarized in Table I . It is evident that a pronounced decrease in tumour incidence occurred at the 3 dose levels in the animals tested, compared with the controls. Taking the 3 dose levels together, 64 out of 143 Data obtained when 1-2 week old mice were nursed by variously treated mothers and injected with 0-01 gEq tumour extract are reported in Table II . A slight reduction in tumour incidence was observed in mice born to MSV-M exposed mothers (87% compared with 97.5% in controls).
However, when tumour incidence was analysed in each single litter, only 3 out of 14 litters showed a decrease in incidence (Table III) . Mice born to mothers immunized post partum showed 100% tumours, in contrast with mice born to mothers immunized long before mating, which presented only 37% tumours, the majority of which eventually regressed. In the latter animals no differences were noted in tumour growth and regression per single litter with regard to the time interval between immunization and parturition. Even 32 weeks after immunization the mother could confer protection against MSV-M tumour development in her offspring (Table IV) .
In order to obtain direct evidence for transfer of maternal immunity, the sera from mothers and their litters were tested for the presence of MSV-M neutralizing antibodies by means of a focus reduction method. From the results shown in Table V , it is clear that sera from immunized mothers and their offspring contained anti-MSV-M antibody (neutralizing titres of 8 and 4 respectively). In contrast, sera from normal mothers and their litters possessed no detectable neutralizing activity.
Behaviour of induced tumours and rescue of MS V-M oncogenic activity
Among the various experimental and control groups described above, no significant differences were observed in the behaviour of MSV-M induced tumours. The survival period of mice bearing progressive tumours was essentially the same, and the mice usually died within 1-3 weeks. Some tumours developed more than 2 months after MSV-M injection. Moreover, in some of the mice whose primary tumours had regressed 2-7 months earlier there was a reappearance of tumours, either at the injection site and/or (Mirand, Grace and Buffet, 1966; Mathot and Scher, 1968; Chieco-Bianchi et al., 1970) ; similar protection against Gross virus in rats has also been reported (Ioachim, 1970 (Bubenik et al., 1969) suggesting that enhancement of tumour growth, rather than suppression, may result following the injection of anti-MSV-M immune serum, it is worthwhile to mention that such an effect has not been noted in the present experiments. It should be pointed out, however, that enhancement of tumour growth in the MSV-M and other tumour systems has been observed for transplanted rather than for developing primary tumours (Harvey and East, 1971; Kaliss, 1969) .
Females immunized post partum did not transfer any protection from MSV-M tumourigenesis to their offspring. The fact that not enough time elapsed to develop an effective antibody titre after immunization might explain this failure. Also, it may be possible that protective antibody transfer occurs exclusively through the placenta during intrauterine life. This last possibility seems most unlikely, however, since passive transmission of maternal immunity in the mouse takes place mainly after birth through colostrum and milk (Brambell, 1970 A reduced number of tumours was also observed in 3 out of 14 MSV-M-injected litters whose mothers had been previously exposed to the virus while nursing infected offspring. A similar observation has been made by Essex et al. (1971) , who found that kittens born to and nursed by mothers that had previously nursed litters injected with feline leukaemia virus were protected from development of tumours following injection of feline sarcoma virus. These findings suggest that horizontal transmission of leukaemia and sarcoma viruses does occur, albeit rarely, and that it may have some practical significance under natural conditions as well (Brodey et al., 1970 (Hartley and Rowe, 1966; Chuat et al., 1969) . It is possible that the immune system of the host is not operationally effective against leukaemia cells due to their lesser immunosensitivity or a ' sneaking through " phenomenon. Another possibility is the fact that leukaemic cell kinetics follow a logarithmic growth curve which is unrelated to the viral supply. Development and growth of MSV-M tumours, on the other hand, seem to depend upon a constantly high rate of virus replication and continuous recruitment of newly infected transformed cells. This last hypothesis, supported by in vitro (Bather, Leonard and Yang, 1968; Parkman, Levy and Ting, 1970) and in vivo findings (Chieco-Bianchi et al., 1971) concurs with our present observation that passive immunity is capable of effecting tumour regression. Thus, when virus synthesis is slowed down by a host reaction or antibody transfer, prevention as well as tumour regression may result.
The recovery of MSV-M oncogenic activity from frankly leukaemic animals, of which some had never presented tumour, implies that MSV-M replicates at low levels during the host's life span. This is further substantiated by the late appearance or recurrence of tumours in some of the MSV-M inoculated mice. In fact, Blumenschein and Moloney (1969) have reported that virus is present in spleens from MSV-M injected mice even 46 days after inoculation, suggesting that the spleen and possibly other reticuloendothelial organs may be the carrier tissues for continuing infection in the animal. These considerations provide grounds for believing that when the host mechanisms constantly operating to limit oncogenic activity are undermined, then MSV-M may reach titres high enough to induce tumours.
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